3Dickson M, Redwood H. Pharmaceutical Reference Prices. How do They, Work in Practice? [J]. Pharmaco Economics, 1998, 14 (5) :471 -9.
4Mossialos E. Pharmaceutical Pricing, Fnancing and Cost Containment in the European Union Member States [ C ]. //Leidl R. Health Care and its Financing in the Single European Market. Amsterdam: IOS Press, 1998.85 - 113.
5Kanavos P, Reinhardt U. Reference Pricing for Drugs: Is it Compatible with U.S. Health Care[J]. Health Affairs 2003, 22(3) : 16 - 30.
6Giuliani G, Selke G, Garattini L. The German Experience in Reference Pricing[J].Health Policy, 1998, 44 : 73 - 85.
7Pavcnik N. Do Pharmaceutical Prices Respond to Potential Patient Out- of- pocket Expenses? [J]. RAND Journal of Economies, 2002,33 (3) :469 -487.
8Aronsson T, Bergman M A, Rudholm N. The Impact of Generic Drug Competition on Brand Name Market Shares Evidence from Micro Data [ J ]. Review of Industrial Organization, 2001,19 : 425 - 435.
9Pulg- Junoy J. Incentives and Pharmaceutical Reimbursement Reforms in Spain[J].Health policy , 2004, 67:149 -165.
10Zweifel P, Crivelly L. Price Regulation of Drugs: Lessons from Germany [ J ]. Journal of Regulatory Economics, 1996, 10:257 - 273.
